# Two phosphAte taRGets in End-stage Renal Disease Trial (TARGET)

Study · id `cardio:ct-nct01994733` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01994733](<https://clinicaltrials.gov/study/NCT01994733>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01994733

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 104 participants.

## Technical summary

Registry record NCT01994733. Randomized; no masking; primary purpose treatment. Start 2014-01 (registry gives no type); primary completion 2015-04 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 104 participants (enrolled count; ClinicalTrials.gov record NCT01994733, source copy `cardio:ctgov-nct01994733-2015-06-23`, retrieved 2026-10-26)
- Start date: 2014-01 (registry gives no type) (ClinicalTrials.gov record NCT01994733, source copy `cardio:ctgov-nct01994733-2015-06-23`, retrieved 2026-10-26)
- Primary completion: 2015-04 (actual) (ClinicalTrials.gov record NCT01994733, source copy `cardio:ctgov-nct01994733-2015-06-23`, retrieved 2026-10-26)
- Completion: 2015-04 (actual) (ClinicalTrials.gov record NCT01994733, source copy `cardio:ctgov-nct01994733-2015-06-23`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT01994733, source copy `cardio:ctgov-nct01994733-2015-06-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01994733-2015-06-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Two phosphAte taRGets in End-stage Renal Disease Trial (TARGET)
- Acronym: TARGET
- Condition: End-stage Renal Disease
- Intervention (Drug): Calcium carbonate ( Intensive phosphate control)
- Intervention (Drug): Calcium carbonate (Liberalized phosphate control)
- Lead sponsor: Unity Health Toronto
- Lead sponsor class: OTHER
- Collaborator: Canadian Institutes of Health Research (CIHR)
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Unity Health Toronto (`cardio:org-unity-health-toronto`)
- Registry lists this organization as a collaborator: Canadian Institutes of Health Research (CIHR) (`cardio:org-canadian-institutes-of-health-research-cihr`)

## Provenance

Content hash: 1569f0fa5549b2ce67fa2825e26b469a90b45fbc919ff67bc078656647750708
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
